Claire Jansson-Knodell, MD: Treating Pregnant Women With Celiac Disease

Video

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

Pregnant women with celiac disease are at an increased risk of a number of negative outcomes, including preeclampsia, placental diseases, obstetric complications, and small for gestational age offspring.

In data presented during the 2023 Digestive Disease Week (DDW) in Chicago, a team of investigators studied outcomes within this patient population.

In the retrospective cohort study, the investigators sued the National Inpatient Sample for all pregnant women who delivered babies between 2015-2019, which included 12 million delivers, 10,555 of which were from women with celiac disease.

The results show pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery (odds ratio [OR], 0.15; 95% confidence interval [CI], 0.09-0.26) compared to the cohort without celiac disease.

However, there was not much of a difference in maternal mortality between the 2 groups [n = 0; 0% vs n = 895; <0.1%; P = 0.7].

For offspring, babies of celiac moms were more likely to be small for gestational age (OR, 1.26; 95% CI, 1.01-1.57) and experience distress (OR, 1.29; 95% CI, 1.17-1.42) during delivery.

In an interview with HCPLive®, Claire Jansson-Knodell, MD, associate staff, Cleveland Clinic, explained what the advice is for pregnant women with celiac disease in an effort to reduce the risk of these types of outcomes.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.